Stock Research for CNBX

Get the due diligence for another stock.

CNBX Stock Chart & Research Data

The CNBX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CNBX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.

CNBX Due diligence Resources & Stock Charts

The CNBX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

Latest Financial News for CNBX

Cannabics has submitted a protocol for the Helsinki Committee to conduct a nationwide study on fresh biopsies treated with a multitude of cannabinoid compounds and chemotherapies TEL AVIV, Israel and BETHESDA, ...

BETHESDA, Maryland and TEL AVIV, Israel, Feb. 7, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has entered into agreement with Wize Pharma, Inc. (WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, and that has distribution rights of known medical formulae related to eye diseases. Initially announced in a press release on June 29, 2018, the two companies have been advancing planning and have concluded, that subject to completing a mutually agreeable business plan and obtaining an expert opinion in order to identify a potential FDA route for ophthalmic therapy containing cannabinoids, each expected to occur within 30 days, that they are ready to form a joint venture (JV) company, for the purpose of researching, developing, and administering cannabinoid formulations to treat ophthalmic disorder indications.

HOD HASHARON, Israel, Feb. 7, 2019 /PRNewswire/ -- Wize Pharma, Inc. ("Wize Pharma" or the "Company") (WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that the Company has signed an agreement to form a joint venture (JV) company for the purpose of researching, developing and administering cannabinoid formulations to treat ophthalmic conditions with Cannabics Pharmaceuticals Inc. ("Cannabics") (OTCQB: CNBX), a world leader in personalized cannabinoid medicine focused on cancer and its side effects. The agreement will become effective subject to receipt of an expert opinion, within 30 days from the date of signing, describing the regulatory pathway for eye drops containing cannabinoids. Upon effectiveness, Wize shall issue 900,000 shares of its common stock to Cannabics and Cannabics shall issue 2,263,944 shares of its common stock to Wize. The agreement shall expire if the parties have not approved a business plan by June 30, 2019.

TEL AVIV, Israel and BETHESDA, Maryland, Jan. 31, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced that it has filed an additional four provisional patent applications with the Israel Patent Office, for cannabinoid-based drugs and treatments, designed for conditions associated with non-epileptic seizures and tremors. Dr. Eyal Ballan and Eyal Barad, co-founders of Cannabics, believe that the company's clinical experience and personalization platform may allow for personalized cannabinoid solutions for conditions and syndromes such as Alcohol Withdrawal Syndrome (AWS), REM related sleep disorder (RBD), Psychogenic non-epileptic seizures (PNES) and Drug-induced tremors, found as extrapyramidal side effects (EPSE).

Stock Market & Investing Books

Enter a stock symbol to view the stock details.

Research stock market information without several bookmarks at once.

General Information / Disclaimer

The resources and various material on this website are provided for informational purposes only and does not constitute an offer to sell, a solicitation to buy, or a recommendation or endorsement for any security or strategy, nor does it constitute an offer to provide investment advisory services by StockStatus. All copyrights belong to their respective owners. This website may contain hypertext links to other websites, which are completely independent of this site. StockStatus makes no representation or warranty as to the accuracy, completeness or authenticity of the information contained in any such hyperlink, and any hyperlink to another person or entity shall not in any manner be construed as endorsement by StockStatus of such person’s or entity’s website, products or services. The website offers no opinion with respect to the suitability of any security or specific investment and all investments involve risk, including loss of principal.